IMPORTANCE Laparoscopic distal gastrectomy is gaining popularity over open distal gastrectomy for gastric cancer because of better early postoperative outcomes. However, to our knowledge, no studies have proved whether laparoscopic distal gastrectomy is oncologically equivalent to open distal gastrectomy.
L aparoscopic gastrectomy has been applied in treatment of gastric cancer, especially early-stage gastric cancer. [1] [2] [3] Compared with open procedures, laparoscopic gastrectomy for gastric cancer offers better short-term postoperative outcomes. [4] [5] [6] Its oncologic safety, however, has remained controversial because of a lack of evidence from welldesigned randomized clinical trials. Most randomized clinical trials testing laparoscopic vs open surgery for early gastric cancer have reported early results on the procedural safety and short-term benefits of the laparoscopic approach. [7] [8] [9] [10] The Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) group has also conducted a multicenter, phase 3 randomized clinical trial (KLASS-01) to provide definitive evidence on the surgical and oncologic safety of laparoscopic distal gastrectomy (LDG) compared with open distal gastrectomy (ODG).
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The KLASS group previously reported the short-term benefits of LDG for clinical stage I gastric cancer, demonstrating shorter hospital stay, less blood loss, and fewer wound complications compared with ODG. 12, 13 The KLASS group has since concluded that LDG for clinical stage I gastric cancer is a surgically safe procedure. In this article, we present the longterm outcomes of our prospective randomized clinical trial comparing LDG and ODG for clinical stage I gastric cancer.
Methods

Study Design and Patients
Our investigator-initiated trial sought to compare short-term clinical outcomes and long-term oncologic results of LDG with those of ODG for clinical stage I gastric cancer (KLASS-01). KLASS-01 was designed as a phase 3, multicenter, openlabel, noninferiority, prospective randomized clinical trial conducted by 15 surgeons from 13 tertiary hospitals in Korea. The study design and methods have been described in detail previously. 11 All patients provided written informed consent before enrollment. The study protocol was approved by the institutional review boards of all participating hospitals (Seoul National University Bundang Hospital, Ajou University Hospital, Dong-A University Hospital, Yeouido St. Mary's Hospital, Seoul National University Hospital, Keimyung University Dongsan Medical Center, Soonchunhyang University Bucheon Hospital, Chonbuk National University Hospital, Seoul St. Mary's Hospital, Chungnam National University Hospital, Chonnam National University Hwasun Hospital, Ewha Womans University Mokdong Hospital, and Severance Hospital). The trial protocol is included in Supplement 1. From January 5, 2006 , to August 23, 2010, we enrolled patients with gastric cancer suitable for distal gastrectomy. Patients were between 20 and 80 years of age. All patients had histologically proven, preoperative clinical stage I gastric adenocarcinoma (T1N0M0, T1N1M0, or T2aN0M0). We excluded patients with the following criteria: American Society of Anesthesiologist score greater than 3, history or presence of other malignant tumors, previous chemotherapy or radiotherapy, and need for combined resection because of other benign conditions except cholecystectomy.
Objectives and End Points
Our primary objective was to demonstrate noninferior oncologic outcomes for LDG vs ODG for clinical stage I gastric cancer. The primary end point was 5-year overall survival calculated from the date of surgery to the date of death from any cause. Secondary end points were gastric cancer-specific survival, morbidity and mortality, quality of life, and cost-effectiveness. Cancer-specific survival was calculated as the number of months from gastrectomy to the date of death from gastric cancer. In the analysis of cancer-specific survival, we censored patients who died of causes other than gastric cancer.
Randomization and Data Management
Patients were enrolled and randomized to undergo LDG or ODG according to a computer-generated randomization list at a 1:1 ratio. Randomization was controlled by a centralized independent data center balancing the treatment arms using 60 codes for each investigator and institution. The patients were allocated in order of the day of enrollment. A trial steering committee was responsible for overseeing the trial. All data were collected by research coordinators at each hospital. To reduce the likelihood of incorrect data, data entry was conducted using a dual data entry procedure by 2 different data entry persons at the data center independent of the participating institutions. The 2 entries were compared, and any discrepancies were corrected. Patient death information was obtained from the Korea Statistics Promotion Institute database, allowing the exact dates of death for all enrolled patients to be collected. Survival and recurrence status was determined in December 2016.
Interventions, Quality Control, and Follow-up
For both approaches, standard radical distal gastrectomy with D1+β or D2 lymphadenectomy according to the Japanese classification was performed.
14 Dissection of lymph node station 14v was optional. For all patients, a partial omentectomy was performed. Decisions on reconstruction methods depended on each surgeon's preference. During LDG, reconstruction was performed extracorporeally through a minilaparotomy of less than 5 cm in the upper abdomen. Adjuvant chemotherapy was
Key Points
Question To participate in the trial, surgeons must have performed at least 100 gastrectomies for gastric cancer by laparoscopic and open surgery (50 each), and hospitals had to have an annual volume of at least 80 gastrectomies. Before initiation of the trial, we established a standardized protocol for each surgical procedure. All candidate surgeons' operations were assessed by 2 experienced surgeons (H.-H.K., W.K., S.-U.H., M.-C.K., G.S.C., and W.J.H.) during on-site visits for quality control. All participating surgeons thoroughly reviewed each other's unedited videos to build consensus on procedural standardization. During the trial, video recordings of all LDG and photographic documentation of the operative field after lymphadenectomy by ODG were mandated. We evaluated morbidity and mortality between the 2 interventions by a planned interim analysis before continuing the study to ensure patient safety. We previously reported the results of this planned interim analysis, demonstrating no difference between the 2 approaches. 12 All patients were followed up regularly, and follow-up data, including recurrence and death, were registered. The same follow-up protocol was used for both groups. Follow-up was conducted every 3 months for the first 2 years after surgery, every 6 months for the next 3 years, and then annually.
Statistical Analysis
The primary and secondary end points were analyzed in 2 different populations. The intention-to-treat population was defined as all eligible patients who were randomized except those excluded after randomization. The per-protocol population was defined as the patients who underwent the assigned approaches only. The patients who required conversion from ODG to LDG were not excluded from the per-protocol population. We planned to perform all analyses on an intention-to-treat population basis.
We calculated the effective sample size using a 5-year overall survival of 90% based on review of literature after open gastrectomy for clinical stage I gastric cancer. [15] [16] [17] We tested the hypothesis that the Kaplan-Meier estimate of 5-year overall survival of LDG would be noninferior to that of ODG within a 5% margin (corresponding hazard ratio [HR] of 1.54). To prove the noninferiority of LDG, the lower limit of the 1-sided 97.5% CI of the difference in 5-year overall survival between the 2 groups should be greater than −5% (LDG minus ODG). Although the original analysis plan for the noninferiority results was using a 1-sided 95% CI, this was changed to a 1-sided 97.5% CI to correspond to recent, more conservative statistical practice. We assumed that the patient registration period would be 4.5 years and the follow-up period would be 5 years. The sample size was estimated using the noninferiority log-rank test. Finally, we calculated that 1400 patients (700 in each group, with at least 633 eligible patients in each intention-to-treat population) were needed to provide 80% power for a 1-sided type I error level of 0.05 and to allow for a dropout rate of 10% after randomization. We used R statistics, version 3.1.1 (R Foundation for Statistical Computing) for data analysis. The χ 2 or Fisher exact tests for categorical variables and t tests or Mann-Whitney tests for continuous variables were used for statistical analyses. KaplanMeier curves were used to estimate overall survival and cancerspecific survival. The HRs and 1-sided 97.5% CIs were estimated with a Cox proportional hazards regression model after confirmation of the proportional hazard assumption. Onesided 97.5% CIs are reported for survival differences and HRs; other CIs are 2-sided 95% CIs unless otherwise specified. We used 2-sided values for the calculation of the P values of the HR for death in the post hoc analysis. 673 in the LDG group and 686 in the ODG group. We excluded another 104 patients from the per-protocol population. Among them, 85 underwent surgery with an approach opposite the one to which they were randomized (63 randomized to the ODG group and 22 to the LDG group). Thus, the per-protocol population included 1255 patients: 644 in the LDG group and 611 in the ODG group ( Figure 1) . The 2 study groups were balanced regarding baseline clinical char- Table 1) .
Results
Patients
Surgical and Pathologic Outcomes
The KLASS group previously reported early postoperative outcomes in detail, 13 although minor differences were found between the patients included in this long-term survival analysis and those in the early postoperative outcomes analysis. For 6 patients (0.9%), LDG was converted to ODG. Regarding postoperative mortality, 4 in-hospital deaths (0.6%) were recorded in the LDG group and 2 (0.3%) in the ODG group. All patients underwent radical gastrectomy with systemic lymphadenectomy (D1+ or D2) except for 1 patient with peritoneal carcinomatosis in the LDG group. Mean numbers of retrieved lymph nodes and patients with fewer than 16 retrieved lymph nodes were similar between the 2 groups. There was no margin involvement of the tumor in any patient. The proportions of histologic types and pathologic TNM stages were similar between the 2 groups ( Table 1) . As for diagnostic accuracy of invasion depth, 72 patients (5.3%) had pathologic T3 tumors and 41 (3.0%) had T4 tumors in the intention-to-treat population. For clinical T1 tumors (n = 1095), 960 (87.7%) were pathologic T1, whereas 84 (7.7%) were pathologic T2, 34 (3.1%) were pathologic T3, and 17 (1.6%) were pathologic T4. For clinical T2 tumors (n = 264), 64 (24.2%) were pathologic T2, whereas 137 (51.9%) were pathologic T1, 38 (14.4%) were pathologic T3, and 24 (9.1%) were pathologic T4.
In total, 126 patients (59 in the LDG group and 67 in the ODG group) received adjuvant chemotherapy. Fifty-one patients (86.4%) in the LDG group and 61 patients (91.0%) in the ODG group received chemotherapy within 6 weeks after surgery (P = .41). The mean (SD) durations from surgery to adjuvant chemotherapy did not differ between the 2 groups (28.7 [13.9] days in the LDG group vs 29.4 [12.3] days in the ODG group; P = .75).
Survival Outcomes
Overall Survival After a median follow-up of 99.8 months, 79 patients (11.7%) in the LDG group died compared with 85 patients (12.4%) in the ODG group by the last follow-up date. Overall causes of death were similar between the 2 groups ( Table 2 ). The 5-year overall survival rates were 94.2% (95% CI, 92.4%-96.0%) for the LDG group and 93.3% (95% CI, 91.4%-95.2%) for the ODG group (log-rank P =. 64) (Figure 2A) . The difference in 5-year overall survival was 0.9 percentage points; the difference in the lower limit of the 97.5% CI was −1.6 percentage points, which was greater than the noninferiority margin of −5% (1-sided 97.5% CI, −1.6 to infinity; HR, 0.93, 1-sided 97.5% CI, −infinity to 1.26). The absence of differences in causes of death (eTable in the Supplement 2), HRs for death, and 5-year overall survival also persisted in the per-protocol population (eFigure1AintheSupplement 2).
Cancer-Specific Survival
By the cutoff date, 28 patients (4.2%) in the LDG group had died of gastric cancer compared with 28 patients (4.1%) in the ODG group. The 5-year cancer-specific survival rates were similar between the 2 groups (97.1% in the LDG group and 97.2% in the ODG group, log-rank P = .91; difference of −0.03 percentage points; 1-sided 97.5% CI, −1.8 to infinity; HR, 0.97; 1-sided 97.5% CI, −infinity to 1.64) ( Figure 2B ). In the perprotocol population, cancer-specific survival was similar to that in the intention-to-treat population (eFigure 1B in Supplement 2).
Recurrence was recorded in 38 patients (5.6%) in the LDG group and 33 patients (4.8%) in the ODG group; the difference was not statistically significant (P = .49). Recurrence patterns for these 2 groups were also similar ( Table 2) . Including patients with mixed recurrence, 13 (1.9%) in the LDG group and 7 (1.0%) in the ODG group experienced locoregional recurrence. In the per-protocol population, we observed similar recurrence rates and patterns as those in the intention-to-treat population (eTable in Supplement 2). .60
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Discussion
In this KLASS-01 trial, we confirmed the noninferiority of 5-year overall survival outcomes for LDG for gastric cancer and better short-term clinical outcomes compared with ODG. We found overall survival, cancer-specific survival, and recurrence patterns after LDG to be similar to those after ODG. Although LDG exhibited longer operation times in our trial, it allowed for less estimated blood loss, fewer postoperative complications, and a shorter hospital stay, as described in a previous report 13 on short-term outcomes of the KLASS-01 trial. Together with these better, or at least similar, early postoperative outcomes and the minimal invasiveness of laparoscopic surgery over open surgery, these long-term oncologic outcomes of LDG support the adoption of this procedure as a standard treatment for clinical stage I gastric cancer. The oncologic safety of laparoscopic surgery for gastric cancer was doubted because of a potentially increased risk of locoregional recurrence caused by inadequate lymphadenectomy.
18 However, we previously observed equivalent surgical and pathologic oncologic efficacy with LDG compared with ODG, achieving both an adequate number of harvested lymph nodes and a safe resection margin with LDG. We thus anticipated comparable long-term oncologic outcomes for overall and cancer-specific survival because these early outcomes indicated the oncologic safety of the laparoscopic procedure. In this trial, the difference in locoregional recurrence between LDG and ODG did not reach statistical significance, although the total number of recurrences was small and the recurrence rate was 0.8% higher with LDG than with ODG. Supporting our results, several large-scale retrospective studies 19, 20 have reported similar long-term oncologic results between laparoscopic and open gastrectomy. Although the survival rates in our trial are somewhat lower than those in the JCOG0703 (Japan Clinical Oncology Group 0703) study, this finding might be explained by a comparatively lower proportion of patients with pathologic stage IA disease in our study. 21 Moreover, 13% of patients in our study had pathologic stage II or more advanced disease, and 15% of patients had lymph node metastasis. Along with minimally invasive advantages of laparoscopic gastrectomy, our trial found decreased morbidity and mortality for LDG compared with ODG within the same study cohort. We also found similar survival in the LDG group compared with that in the ODG group regardless of BMI, although the mean BMI of the patients was less than that of Western patients. Thus, our results on the noninferiority of LDG in regard to survival compared with ODG suggest potential benefits in obese or even morbidly obese patients, even if lymphadenectomy may be more difficult by laparoscopy in obese patients. We strived to maintain the quality of the trial by using hospitals' and surgeons' case volumes as eligibility criteria as well as evaluation of surgeons' technical proficiency. Our study revealed satisfactory surgical outcomes for both approaches. Moreover, the mean number of patients enrolled in the study was 108.9 patients per hospital and 23.3 patients per hospital each year. These numbers are greater than those registered in any other surgical trial on this topic to our knowledge.
Limitations
Our trial has several limitations. First, we only included patients with clinical stage I cancer suitable for distal subtotal gastrectomy. Applying laparoscopic surgery for more advanced cancers and different operations, such as total gastrectomy, needs to be verified through other clinical trials. Accordingly, the KLASS-02 trial is being conducted to compare LDG with ODG for locally advanced gastric cancer.
22,23 The KLASS-06 trial is in the planning stages to compare laparoscopic total gastrectomy with open surgery for advanced gastric cancer located in the upper body of the stomach. Second, after randomization, the surgical approaches crossed over from ODG to LDG in 63 patients and from LDG to ODG in 22 patients. Increasing interest in laparoscopic surgery among patients on initiation of the KLASS-01 trial may have influenced these patients' decisions to switch surgical approaches after randomization. However, analysis of the perprotocol population after excluding these crossover patients revealed the same long-term oncologic results.
Third, it would be difficult to verify the generalizability of our findings to surgeons and centers with less experience. Along with an accumulation of cases, proper education and training, such as participation in a laparoscopic gastrectomy team of experts and proctoring program, would help surgeons and centers with less experience perform laparoscopic gastrectomy safely and reduce the learning curve period. [24] [25] [26] In addition, studies [27] [28] [29] anastomosis because an easier and faster reconstruction can be achieved intracorporeally in laparoscopic procedures, especially in patients with a high BMI. Fifth, the 5% noninferiority margin of the 5-year overall survival rate was large compared with the observed 5-year overall mortality of approximately 6.7% in the ODG group. However, the difference in the 5-year overall survival rate was 0.9 percentage points, which was within the lower limit of the 97.5% CI of −1.6%. Thus, we can rule out a larger decrease in 5-year overall survival.
Sixth, the period of follow-up was relatively short compared with the median survival time for patients; therefore, we only observed the first part of the survival curve, leaving open the possibility that the observed noninferiority may not be maintained in the long term. Thus, a study with more longterm follow-up results is warranted.
Conclusions
We found that, when used for clinical stage I gastric cancer, LDG is associated with low morbidity and with survival comparable to those for ODG without compromising long-term oncologic outcomes. Our trial supports the use of LDG as a standard treatment option for clinical stage I distal gastric cancer when it can be performed by surgeons with sufficient experience. 
2) Increase in early gastric cancer
The introduction of endoscopy has led to a significant increase in the diagnosis of early gastric cancer.
According to a report by the Korean Gastric Cancer Association, the proportion of early gastric cancer rose from 28.6% in 1995 to 32.8% in 1999. 1 This trend was more prominent in the case of Japan, with a 2000 study by Maehara et al. showing an increase in the proportion of early gastric cancer from 18% to 57% in the past twenty years. Early gastric cancer refers to invasive gastric cancer that invades no more deeply than the submucosa, regardless of lymph node metastasis. Curative resection is possible in most cases, and if performed, at least 95% of patients achieve long-term survival without recurrence. The
General Surgery Department of Seoul National University Hospital observed 1,452 patients who had received curative resection for early gastric cancer from 1986 to 1995, and reported a 5-year recurrence rate of 1.8%, which is equivalent to 26 patients. 2 Following the successful treatment of early gastric cancer, research on surgical procedures has begun to focus on the improved survival rate and the quality of life (QOL) of patients. Given the lack of scientific evidence on the superiority of laparoscopic surgery, the increase in laparoscopic gastrointestinal surgery may be the result of surgeons' efforts to keep up with the changing times. Given the high cure rate of at least 90% using current methods, extra caution must be exercised when presenting a new surgical procedure for early gastric cancer. More objective and scientific evidence is required on the standardization of laparoscopic surgical procedures, the stability of laparoscopic surgery, recurrence and survival rates, QOL after laparoscopic surgery, and surgical costs.
6) Significance of research in Korea
Active research is being conducted on the advantages offered by laparoscopic surgery in the treatment of gastric cancer, but most studies are retrospective, and the handful of prospective studies have only been performed on small groups. Large-scale, multi-institutional, prospective, randomized research on the short-term benefits and long-term survival of laparoscopic surgery for gastric cancer has not been attempted.
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If Korea pursues multi-institutional, large-scale, prospective, randomized research in this field, it will be the first of its kind in the world. Since Korea and Japan have seen greater success in the treatment of gastric cancer than the West, the prospective, randomized research by surgeons with extensive experience in laparoscopic surgery for gastric cancer is expected to produce highly significant results.
7) Feasibility and validity
The doctors participating in this study specialize in gastric surgery, and the general surgeons have performed open gastrectomy and laparoscopic gastrectomy at least 50 times each. The affiliated hospitals treat more than 80 cases of gastric cancer in a year. In addition to the retrospective analysis, the results of laparoscopic gastrectomy performed by the participating surgeons were analyzed as a preliminary study. IIIa, 2 (0.3%) in IIIb, and 1 (0.1%) in IV. The incidence of post-surgery complications and mortality were 13.0% (94 cases) and 0.6% (4 cases), respectively. Wound infection was the most common at 4%, followed by intra-abdominal bleeding at 2.2%, intra-abdominal abscess at 1.6%, gastrointestinal bleeding at 1.2%, anastomotic leakage at 1.1%, intestinal obstruction at 0.8%, and anastomotic stricture at 0.6%.
The time taken to pass gas after surgery was 3. 
Number of research subjects
The number of required cases is 1400 (700 cases of laparoscopic gastrectomy and 700 cases of open gastrectomy).
Basis of calculation
This study calculates the effective number of subjects based on the 5-year overall survival rate after open gastrectomy. The assumptions are listed below.
1) Significance level =0.05
2) Type II error ( ) is set as 0.20 to maintain a power of 80%.
3)
The number of open gastrectomy cases is the same as the number of laparoscopic gastrectomy cases.
[n1 (number of open gastrectomy cases) = n2 (number of laparoscopic gastrectomy cases)] 4) Based on previous literatures, the 5-year overall survival rate (p1) of open gastrectomy is presumed to be 90%. The same is assumed for laparoscopic gastrectomy (p2). In this study, we set the non-inferiority margin at 5% (non-inferiority test).
5) H0: p1-p2≤ vs H1: p1-p2>
6) The survival functions of both groups follow an exponential, and proportional hazards is assumed.
** Calculation process
Non-inferiority margin of 5%
The survival function of open gastrectomy and laparoscopic gastrectomy is S1(t)=exp(-1t) and S2(t)=exp(-2t) respectively. Since the ratio of hazards between the two groups i s 0=ln(0.85)/ln(0.9)=1.5403. The null hypothesis and alternative hypothesis are as follows.
H0: ≥ 0 vs. H1: < 0
Assuming n1=n2, the proportion of patients in each group represented by 1 and 2 is 0.5, the patient registration period a is 2.5 years, the follow-up observation period b is 5 years, and the common hazards rate of the two groups under the alternative hypothesis is =-1/5ln(0.85)=0.0325.
Formula
The number of patients required in each group is n=D/d.
Target number (Unit: persons) Laparoscopic Open Total
Final number of subjects 633 633 1266
Number of subjects including withdrawal rate (10%) 700 700 1400
Clinical trial methods
Conditions for participating surgeons and standardization of surgery
The surgeons participating in the trial were to have conducted at least 50 cases each of LADG and ODG, and each participant's institution was to conduct at least 80 cases each year for surgical quality control. We established a standardized protocol of the procedure, and all of the surgeons' operation quality was assessed by 2 experienced surgeons' site visits. Then, all of the participating surgeons thoroughly reviewed each other participant's unedited videos for the standardization and quality control of the study.
To apply standardized procedures to all aspects of the surgery, video-based reviews and discussions will continue to be held after the start of clinical trials. Video recordings will be made for all laparoscopic surgery, and field photos will be taken after gastrectomy in the case of open surgery.
Institutional participation and patient registration
1) Patient registration will begin after obtaining approval from the institutional review board of affiliated institutions.
2) Method of patient registration
General instructions on clinical trials are provided to obtain informed consent from patients who satisfy all selection criteria and none of the exclusion criteria. A researcher of Seoul National University Bundang Hospital, the principal institution, reviews the eligibility of selected subjects before registration and randomization.
3) Considerations for registration
Patients are rejected if they refuse to participate after registration or do not undergo surgery within 30 days of registration.
For patients to participate in clinical trials after the 30-day limit, they must be reassessed according to the initial registration criteria and provide consent again.
4) Completion period
Registration will end when the number of randomized, registered subjects reaches 1,400.
5) Randomization method
A randomized table prepared by an independent data management group was used, and 60 codes are assigned by institution and researcher. Randomization is performed such that each researcher is assigned to one subject, and block randomization is carried out. The size of blocks remains undisclosed to researchers.
Two copies of the randomization table are made, and each stored by the researcher and the data management group. Research subjects are randomly assigned to the control group or test group, and the monitors of each institution are kept informed.
Treatment details and collection of results
Histopathological details determined based on pre-surgery records, surgical findings and results are recorded in the given form. The form is stored by researchers, and one copy is delivered to the institutional monitor during the regular meeting.
Effectiveness assessment
Follow-up surveys are performed over the long term, and the details to be recorded include surgery time, amount of blood loss, amount of blood transfusion, length of stay, early complications, late complications, recurrence and death. These surveys are standardized beforehand, and performed by all institutions in the same method and interval.
1) Factors affecting QOL
The factors affecting QOL after surgery were the scope of gastrectomy, cancer stage and anticancer drug administration. The factors affecting recovery after surgery were the insertion of nanogastric tubes, surgery time and dissection of lymph nodes. Gastrectomy for both groups was in the form of subtotal gastrectomy. Most patients had been diagnosed with gastric cancer, and only a few with advanced gastric cancer. These factors were considered as having little influence on QOL. The same anticancer drugs will be administered to patients in stage 2 or worse to minimize error. The insertion of nanogastric tubes has been associated with severe throat pain and slow restoration of gastrointestinal function. Nanogastric tubes were not inserted based on reports of successful gas removal during surgery without such insertion.
2) Post-surgery pain -PCA (Patient-Controlled Analgesia) administration: To reduce pain adjustment differences arising from the type of PCA administration, intravenous administration was adopted for the research. Subjects were trained to self-administer analgesics whenever they experienced any post-surgery pain, and the amount 
7) EORTC QLQ-C30
While various methods exist for the assessment of patients' QOL by doctors, emotional changes or social adaptation is difficult to measure, and doctors may prioritize factors considered unimportant by patients.
The QLQ-C30 questionnaire developed by EORTC is an example of a patient-centered questionnaire. It includes five functional scales (physical, role, emotional, cognitive, and social functioning) and symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, loss of appetite, constipation, diarrhea), and scales for general health and QOL. Patient responses are converted to a score from 0 to 100.
In principle, the questionnaire is administered one year after surgery.
8) STO22
The STO22 has five multi-item scales (dysphasia, eating restriction, pain, reflux, and anxiety) and four single items (dry mouth, body image, taste and hair loss). Patient responses are converted to a score from 0 to 100. First, multi-trait scaling analysis must be performed to check the Korean translation of STO22 against the original version. If the correlation between items and scales is greater than 0.4, scale classification can be considered appropriate.
Second, the reliability and validity of the Korean STO22 must be assessed. To assess the reliability of the Korean STO22, Cronbach's alpha is obtained using the internal consistency method. A Cronbach's alpha of 0.7 or higher is considered acceptable. To assess the validity of the Korean STO22, ANOVA test was performed on ECOG PS and STO22 items. Given the similarity of STO22 items and QLQ-C30, the correlation between similar items is also examined.
After verifying the reliability and validity of the Korean STO22, average values for laparoscopic gastrectomy and open gastrectomy can be compared and analyzed.
9) Recurrence
Regardless of survival and mortality, all details concerning recurrence must be accurately recorded. These include the date of recurrence, location, type and method of verification.
The recurrence pattern is classified into eight categories: remnant gastric, locoregional, peritoneal, hepatic and extrahepatic hematogenous, lymphatic, mixed, and other recurrences. Remnant gastric recurrence includes tumors in the anastomosis or gastric stump.
Locoregional recurrence includes tumors in adjacent organs, including the gastric bed, porta hepatis, abdominal wall and the regional lymph nodes (perigastric, left gastric, common hepatic, celiac, and hepatoduodenal).
Peritoneal recurrence is defined as peritoneal seeding or Krukenberg's tumor.
Hematogenous metastasis is divided into hepatic and extrahepatic hematogenous recurrence. The latter includes recurrence in the lung, bone, brain, or other distant sites.
Lymphatic recurrence is defined as tumors in the paraaortic, inguinal, Virchow's or other distant lymph nodes, or lung lymphangitic metastasis.
The mixed pattern of recurrence includes those recurrences where the criteria for two or more of the above categories are met simultaneously
10) Death
Details such as date of death, cause of death and method of verification must be recorded. Intermediate assessment is performed based on the collected data.
For cases that cannot be tracked in follow-up surveys, researchers will attempt to contact the subjects by phone or mail.
11) Inflammatory and immune responses
CRP and IL-6 were used as markers of inflammatory response for patients in both groups. To compare immunity, measurements were taken for total lymphocyte, T-subset, B cell, NK cell count, IL-2, and TNF-. These values were obtained before surgery, two hours after surgery, 24 hours after surgery, five days after surgery and 30 days after surgery. CRP and IL-6 are known to increase two hours after surgery.
Blood samples were centrifuged at 3,000 rpm for five minutes and stored at -75°C~-80°C. After transferring samples from 1,000 patients to the laboratory, CRP and IL-5 were measured using latexenhanced immunoturbidimetric assay and enzyme-linked immunosorbent assays (ELISA) respectively.
CRP and IL-5 levels were first recorded for the 1,000 patients immediately after registration for the study. The influence of inflammatory response on survival rates was analyzed following the analysis of 5-year survival.
12) Cost-effectiveness
At discharge, the total cost will be calculated and the two groups will be compared with regard to costeffectiveness. We evaluated not only social cost which may be calculated by time needed to resume normal social activity but also "willingness to pay" reflecting individual patient preference for a particular procedure. Information regarding factors affect cost (length of hospital stay, complications, presence of comorbidity, etc.) will be collected. 
Analysis period and final analysis
1) Analysis period
Except in cases approved by the steering committee, the two groups will not be compared in terms of five-year overall survival, disease-free survival, and extent of recovery.
2) Intermediate analysis
Intermediate analysis is performed at one-year intervals even while clinical trials are being carried out.
The results of analysis are provided to all researchers, and the possibility of early conclusion is determined. The trials are immediately halted if surgery-related deaths exceed 5%.
3) Final analysis
Final analysis is performed for all date upon completion of the five-year follow-up of all registered patients. A final report and summary are prepared based on the analysis.
The final report and summary are submitted to research participants and the steering committee of the Korean Laparoendoscopic Gastrointestinal Surgery Study Group (KLASS).
The steering committee concludes clinical trials after writing a comprehensive report based on the final report.
Once clinical trials are complete, all data will be under the ownership of the supervisor. Further materials may be provided in consultation with the steering committee if requested by research committees.
Safety measures for research subjects
-Expected side effects and risks for research subjects
Complications (heat and lung complications, bleeding, infection, anastomotic issues) related to all open gastrectomy and laparoscopic gastrectomy are the same as previously reported.
-Nondisclosure of identity
Patients' medical records will be kept confidential, and anonymity will be maintained even when results are presented.
-Abnormal reaction: All side effects occurring during the research will be recorded to derive the proportion of abnormal reactions. The incidence of abnormal reactions and confidence interval will be obtained for the test group and control group, and analysis will be performed using chi-square test.
Regulations on compensation for research subjects
Before conducting clinical trials, the principal investigator must check the following.
1) The principal investigator will assume responsibility and provide compensation if research subjects experience physical damage in the process of resolving abnormal reactions and treatment or hospitalization is required.
2) The principal investigator will exert all efforts to ensure no disadvantage to subjects in the clinical trials in accordance with these regulations. 
